Compare CSPI & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSPI | ARMP |
|---|---|---|
| Founded | 1968 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.8M | 125.7M |
| IPO Year | 1987 | N/A |
| Metric | CSPI | ARMP |
|---|---|---|
| Price | $11.81 | $6.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 21.3K | ★ 47.0K |
| Earning Date | 02-09-2026 | 11-12-2025 |
| Dividend Yield | ★ 1.02% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $58,730,000.00 | $5,054,000.00 |
| Revenue This Year | N/A | $4.48 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 6.36 | N/A |
| 52 Week Low | $9.65 | $0.90 |
| 52 Week High | $21.95 | $16.34 |
| Indicator | CSPI | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 43.66 | N/A |
| Support Level | $11.51 | N/A |
| Resistance Level | $12.03 | N/A |
| Average True Range (ATR) | 0.57 | 0.00 |
| MACD | -0.08 | 0.00 |
| Stochastic Oscillator | 29.89 | 0.00 |
CSP Inc develops and markets IT integration solutions, security products, managed IT services, cloud services, purpose-built network adapters, and high-performance cluster computer systems. The firm operates in two segments, namely Technology Solutions, where the company focuses on value-added reseller integrated solutions, including third-party hardware, software, and technical computer-related consulting, and High-Performance Products segments, where the company designs, manufactures, and delivers products and services to customers that require specialized cybersecurity services, networking, and signal processing. It generates a majority of its revenue from the Technology Solutions segment. Geographically, the company generates the majority of its revenue from the Americas.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.